Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block vs Bupivacaine Alone for Hemodynamics Stability in Craniotomy

NACompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 10, 2024

Primary Completion Date

September 10, 2024

Study Completion Date

September 10, 2024

Conditions
DexmedetomidineCraniotomyRegional AnesthesiaMean Arterial Pressure Stability
Interventions
DRUG

Scalp block with bupivacaine alone

In Group SB: (LA) was done by 20ml of Bupivacaine 0.25%. maximal dose of Bupivacaine did not exceed (2.5 mg/kg) Scalp nerve block will be done by anesthesiologist who is blind to the drug being injected and under complete septic condition where local infiltration of local anesthetic (LA) will be done guided by bony superficial landmarks to block the supraorbital, supratrochlear, auriculotemporal, occipital, and post auricular branches of the greater auricular nerves

DRUG

Scalp block by adding dexmedetomidine as an adjuvant to bupivacaine

local infiltration of total volume 20ml which include (Bupivacaine 0.25%. + Dexmedetomidine 1mcg/kg) was done Dexmedetomidine preparation was done by 2ml (200 mcg) diluted by 18 ml normal saline in 20 ml syringe as 1ml was contain 10 mcg and injected at same points as above

Trial Locations (1)

11111

Ain Shams university, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT06951256 - Dexmedetomidine as an Adjuvant to Bupivacaine in Scalp Block vs Bupivacaine Alone for Hemodynamics Stability in Craniotomy | Biotech Hunter | Biotech Hunter